Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carl H June

Showing results (181-190 of 460) with videos related to

Pageof 46
Sort By:
Oncoimmunology|March 5, 2016
T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastomaNathan Singh, Irina Kulikovskaya, David M Barrett, et al.
Nano Letters|April 21, 2026
HITE: HIV Inspired Lipid Nanoparticle Platform for CAR T Cell EngineeringDongyoon Kim, So-Jeong Moon, Emily L Han, et al.
Science Translational Medicine|October 29, 2010
The inducible costimulator (ICOS) is critical for the development of human T(H)17 cellsChrystal M Paulos, Carmine Carpenito, Gabriela Plesa, et al.
Human Gene Therapy|September 2, 2009
4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignanciesSyam Tammana, Xin Huang, Marianna Wong, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2009
Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytesYozo Nakazawa, Leslie E Huye, Gianpietro Dotti, et al.
Nature Biomedical Engineering|March 16, 2024
Author Correction: Small-molecule-mediated control of the anti-tumour activity and off-tumour toxicity of a supramolecular bispecific T cell engagerNingqiang Gong, Xuexiang Han, Lulu Xue, et al.
Transplantation|July 25, 2006
Suppressor function of umbilical cord blood-derived CD4+CD25+ T-regulatory cells exposed to graft-versus-host disease drugsStephen B Porter, Baoling Liu, John Rogosheske, et al.
Nature Biomedical Engineering|February 20, 2024
Small-molecule-mediated control of the anti-tumour activity and off-tumour toxicity of a supramolecular bispecific T cell engagerNingqiang Gong, Xuexiang Han, Lulu Xue, et al.
Leukemia|March 13, 2021
CAR T cells targeting CD13 controllably induce eradication of acute myeloid leukemia with a single domain antibody switchXin He, Zijie Feng, Jian Ma, et al.
Cancer Research|May 3, 2011
Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010Hildegund C J Ertl, John Zaia, Steven A Rosenberg, et al.
Pageof 46

Showing results (181-190 of 460) with videos related to

Sort By:
Pageof 46
Oncoimmunology|March 5, 2016
T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastomaNathan Singh, Irina Kulikovskaya, David M Barrett, et al.
Nano Letters|April 21, 2026
HITE: HIV Inspired Lipid Nanoparticle Platform for CAR T Cell EngineeringDongyoon Kim, So-Jeong Moon, Emily L Han, et al.
Science Translational Medicine|October 29, 2010
The inducible costimulator (ICOS) is critical for the development of human T(H)17 cellsChrystal M Paulos, Carmine Carpenito, Gabriela Plesa, et al.
Human Gene Therapy|September 2, 2009
4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignanciesSyam Tammana, Xin Huang, Marianna Wong, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2009
Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytesYozo Nakazawa, Leslie E Huye, Gianpietro Dotti, et al.
Nature Biomedical Engineering|March 16, 2024
Author Correction: Small-molecule-mediated control of the anti-tumour activity and off-tumour toxicity of a supramolecular bispecific T cell engagerNingqiang Gong, Xuexiang Han, Lulu Xue, et al.
Transplantation|July 25, 2006
Suppressor function of umbilical cord blood-derived CD4+CD25+ T-regulatory cells exposed to graft-versus-host disease drugsStephen B Porter, Baoling Liu, John Rogosheske, et al.
Nature Biomedical Engineering|February 20, 2024
Small-molecule-mediated control of the anti-tumour activity and off-tumour toxicity of a supramolecular bispecific T cell engagerNingqiang Gong, Xuexiang Han, Lulu Xue, et al.
Leukemia|March 13, 2021
CAR T cells targeting CD13 controllably induce eradication of acute myeloid leukemia with a single domain antibody switchXin He, Zijie Feng, Jian Ma, et al.
Cancer Research|May 3, 2011
Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010Hildegund C J Ertl, John Zaia, Steven A Rosenberg, et al.
Pageof 46